Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712930 · ClinicalTrials.gov registry record · Phase 2
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
A Phase 2 study, sponsored by BeiGene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03712930 is a Phase 2 study that was terminated before completion, run by BeiGene. The registered enrollment target is 13 participants.
The verdict
NCT03712930, a Phase 2 study, was terminated before completion, sponsored by BeiGene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy of pamiparib in participants with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency (CTC-HRD). All participants will receive pamiparib. The purpose of this study is to demonstrate that pamiparib will improve Objective Response Rate (ORR) and Prostate-Specific Antigen (PSA) response rate
Interventions
- DRUG Pamiparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-02-05 |
| Est. Completion | 2020-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712930
The ClinicalTrials.gov registry entry for NCT03712930 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pamiparib is the first listed.
NCT03712930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712930 about?
NCT03712930 is a clinical study titled "Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency". This study is designed to evaluate the efficacy of pamiparib in participants with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency (CTC-HRD). All participants will receive pamiparib. The purpose of this study ...
What is the current status of trial NCT03712930?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-02-05. Estimated completion is 2020-09-02.
What interventions are being tested in trial NCT03712930?
The interventions under investigation include: Pamiparib (DRUG).
Who is sponsoring clinical trial NCT03712930?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.